These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26730185)

  • 1. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients.
    Park HY; Lee H; Koh WJ; Kim S; Jeong I; Koo HK; Kim TH; Kim JW; Kim WJ; Oh YM; Sin DD; Lim SY; Lee SD;
    Int J Chron Obstruct Pulmon Dis; 2016; 11():23-30. PubMed ID: 26730185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.
    Siddiqui SH; Pavord ID; Barnes NC; Guasconi A; Lettis S; Pascoe S; Petruzzelli S
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3669-3676. PubMed ID: 30464449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome.
    Lee SY; Park HY; Kim EK; Lim SY; Rhee CK; Hwang YI; Oh YM; Lee SD; Park YB
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2797-2803. PubMed ID: 27877033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
    Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
    Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
    van Geffen WH; Tan DJ; Walters JA; Walters EH
    Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD.
    Cheng SL; Wang HH; Lin CH
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2231-2238. PubMed ID: 28814851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
    Suissa S; Dell'Aniello S; Ernst P
    Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
    Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
    NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
    Kew KM; Dias S; Cates CJ
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled corticosteroids, blood eosinophils, and FEV
    Whittaker HR; Müllerova H; Jarvis D; Barnes NC; Jones PW; Compton CH; Kiddle SJ; Quint JK
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1063-1073. PubMed ID: 31213788
    [No Abstract]   [Full Text] [Related]  

  • 16. Stepwise management of COPD: What is next after bronchodilation?
    Miravitlles M; Matsunaga K; Dreher M
    Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
    Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
    Greulich T; Kostikas K; Gaga M; Aalamian-Mattheis M; Lossi NS; Patalano F; Nunez X; Pagano VA; Fogel R; Vogelmeier CF; Clemens A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1229-1237. PubMed ID: 29713156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.